The dual, opposing roles of estrogen in the prostate

Annals of the New York Academy of Sciences

Volumn 1155, Issue , 2009, Pages 174-186

  Ellem, Stuart J ^a,b   Risbridger, Gail P ^a  

^a MONASH UNIVERSITY   (Australia)

^b NONE   (Australia)

Author keywords

Aromatase; ER ; ER ; Estrogen; Prostate; Prostatitis

Indexed keywords

ANDROGEN; AROMATASE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; GONADOTROPIN; ISOFLAVONE; PHYTOESTROGEN; TESTOSTERONE; TOREMIFENE;

ADVERSE OUTCOME; ANDROGEN SYNTHESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER INHIBITION; CANCER MODEL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE MODEL; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; HOMEOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; ORGAN GROWTH; ORGANOGENESIS; PROSTATE; PROSTATE CANCER; PROSTATE EPITHELIUM; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

EID: 61749095503     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04360.x     Document Type: Conference Paper

References (106)

1. Cunha, G. et al. 1987. The endocrinology and developmental biology of the prostate. Endocr. Rev. 8 : 338 362.
2. Isaacs, J.T., Y. Furuya & R. Berges. 1994. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin. Cancer Biol. 5 : 391 400.
3. Huggins, C. & C.V. Hodges. 1941. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen interaction on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1 : 293 297.
4. Wu, J.P. & F.L. Gu. 1987. The prostate 41-65 years post castration. An analysis of 26 eunuchs. Chin. Med. J. (Engl.) 100 : 271 272.
5. Vermeulen, A., R. Rubens & L. Verdonck. 1972. Testosterone secretion and metabolism in male senescence. J. Clin. Endocrinol. Metab. 34 : 730 735.
6. Vermeulen, A. et al. 2002. Estradiol in elderly men. Aging Male 5 : 98 102.
7. Baulieu, E.E. 2002. Androgens and aging men. Mol. Cell Endocrinol. 198 : 41 49.
8. Gray, A. et al. 1991. An examination of research design effects on the association of testosterone and male aging: Results of a meta-analysis. J. Clin. Epidemiol. 44 : 671 684.
9. Gray, A. et al. 1991. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 73 : 1016 1025.
10. Culig, Z. et al. 1993. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 7 : 1541 1550.
11. Griffiths, K. 2000. Estrogens and prostatic disease. International Prostate Health Council Study Group. Prostate 45 : 87 100.
12. Zumoff, B. et al. 1982. Abnormal levels of plasma hormones in men with prostate cancer: Evidence toward a "two-disease" theory. Prostate 3 : 579 588.
13. Stone, N.N. et al. 1987. Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions. Urol. Res. 15 : 165 167.
14. Kaburagi, Y. et al. 1987. The possibility of aromatization of androgen in human prostate. J. Steroid Biochem. 26 : 739 742.
15. Matzkin, H. & M.S. Soloway. 1992. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 21 : 309 314.
16. Tsugaya, M. et al. 1996. Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer. Int. J. Urol. 3 : 292 296.
17. Hiramatsu, M. et al. 1997. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 31 : 118 124.
18. Negri-Cesi, P. et al. 1998. Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 34 : 283 291.
19. Harada, N., T. Utsumi & Y. Takagi. 1993. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc. Natl. Acad. Sci. USA 90 : 11312 11316.
20. Ellem, S.J. et al. 2004. Local aromatase expression in human prostate is altered in malignancy. J. Clin. Endocrinol. Metab. 89 : 2434 2441.
21. Chen, S. et al. 2002. Transcriptional regulation of aromatase expression in human breast tissue. J. Steroid Biochem. Mol. Biol. 83 : 93 99.
22. Miller, W.R. & J. Jackson. 2003. The therapeutic potential of aromatase inhibitors. Expert Opin. Investig. Drugs 12 : 337 351.
23. Santen, R.J. et al. 2001. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer 92 : 2095 2101.
24. Jones, M.E. et al. 2006. Of mice and men: The evolving phenotype of aromatase deficiency. Trends Endocrinol. Metab. 17 : 55 64.
25. McPherson, S. et al. 2001. Elevated androgens and prolactin in aromatase deficient (ArKO) mice cause enlargement but not malignancy of the prostate gland. Endocrinol. 142 : 2458 2467.
26. Andrews, G. 1951. The histology of the human foetal and prepubertal prostates. J. Anat. 85 : 44 54.
27. Zondek, T. & L.H. Zondek. 1975. The fetal and neonatal prostate. In Normal and Abnormal Growth of the Prostate. M. Goland, Ed. Charles C. Thomas. Springfield, IL.
28. Goodwin, W.E. & R.H. Cummings. 1984. Squamous metaplasia of the verumontanum with obstruction due to hypertrophy: Long-term effects of estrogen on the prostate in an aging male-to-female transsexual. J. Urol. 131 : 553 554.
29. Tunn, U. et al. 1979. Biochemical and histological studies on prostates in castrated dogs after treatment with androstenediol, oestradiol and cyproterone acetate. Acta Endocrinol. (Copenh.) 91 : 373 384.
30. Deschamps, J.C. et al. 1987. Effects of zeranol on reproduction in beef bulls: Scrotal circumference, serving ability, semen characteristics, and pathologic changes of the reproductive organs. Am. J. Vet. Res. 48 : 137 147.
31. Weijman, J. et al. 1992. Changing cytokeratin expression patterns in diethylstilbestrol dipropionate-induced metaplastic lesions of the goat prostate. Vet. Q. 14 : 2 7.
32. Andersson, H. & L.E. Tisell. 1982. Morphology of rat prostatic lobes and seminal vesicles after long-term estrogen treatment. Acta Pathol. Microbiol. Immunol. Scand. [A] 90 : 441 448.
33. Aumuller, G. et al. 1982. Phenotypic modulation of the canine prostate after long-term treatment with androgens and estrogens. Prostate 3 : 361 373.
34. Driscoll, S.G. & S.H. Taylor. 1980. Effects of prenatal maternal estrogen on the male urogenital system. Obstet. Gynecol. 56 : 537 542.
35. Habenicht, U.F. & M.F. el Etreby. 1988. The periurethrals zone of the prostate of the cynomolgus monkey is the most sensitive prostate part for an estrogenic stimulus. Prostate 13 : 305 316.
36. van Kesteren, P. et al. (1996. Effects of estrogens only on the prostates of aging men. J. Urol. 156 : 1349 1353.
37. Pylkkanen, L. et al. 1991. Regional differences in the prostate of the neonatally estrogenized mouse. Prostate 18 : 117 129.
38. Randles, J.L. 1990. Clinical, pathological and histopathological findings in lambs implanted with a growth-promoting product containing progesterone and oestradiol. J. S. Afr. Vet. Assoc. 61 : 126 127.
39. Sugimura, Y. et al. 1988. Temporal and spatial factors in diethylstilbestrol-induced squamous metaplasia of the developing human prostate. Hum. Pathol. 19 : 133 139.
40. Risbridger, G.P. et al. 2001. The metaplastic effects of estrogen on mouse prostate epithelium: Proliferation of cells with basal cell phenotype. Endocrinol. 142 : 2443 2450.
41. Bonkhoff, H., U. Stein & K. Remberger. 1994. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24 : 114 118.
42. Li, X. et al. 2001. Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase. Endocrinol. 142 : 2435 2442.
43. Prins, G.S. et al. 2001. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: Studies with alphaERKO and betaERKO mice. Cancer Res. 61 : 6089 6097.
44. Pylkkanen, L. et al. 1993. Prostatic dysplasia associated with increased expression of c-myc in neonatally estrogenized mice. J. Urol. 149 : 1593 1601.
45. Rajfer, J. & D.S. Coffey. 1978. Sex steroid imprinting of the immature prostate. Long-term effects. Invest. Urol. 16 : 186 190.
46. Prins, G.S. 1992. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinol. 130 : 3703 3714.
47. Prins, G. et al. 1993. Effects of neonatal estrogen exposure on prostatic secretory genes and their correlation with androgen receptor expression in the separate prostate lobes of the adult rat. Endocrinol. 132 : 2387 2398.
48. Higgins, S.J. et al. 1981. Functional development of sex accessory organs of the male rat. Use of oestradiol benzoate to identify the neonatal period as critical for development of normal protein-synthetic and secretory capabilities. Biochem. J. 194 : 895 905.
49. Naslund, M.J. & D.S. Coffey. 1986. The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. J. Urol. 136: 1136-.
50. Prins, G. 1997. Developmental estrogenization of the prostate gland. In Prostate: Basic and Clinical Aspects. R. Naz, Ed 245 263. CRC Press. New York.
51. Gaytan, F. et al. 1986. Morphometric analysis of the rat ventral prostate and seminal vesicles during prepubertal development: Effects of neonatal treatment with estrogen. Biol. Reprod. 35 : 219 225.
52. Rajfer, J. & D.S. Coffey. 1979. Effects of neonatal steroids on male sex tissues. Invest. Urol. 17 : 3 8.
53. Singh, J. & D.J. Handelsman. 1999. Morphometric studies of neonatal estrogen imprinting in the mature mouse prostate. J. Endocrinol. 162 : 39 48.
54. Singh, J. & D.J. Handelsmann. 1999. Imprinting by neonatal sex steroids on the structure and function of the mature mouse prostate. Biol. Reprod. 61 : 200 208.
55. Cattanach, B.M. et al. 1977. Gonadotrophin-releasing hormone deficiency in a mutant mouse with hypogonadism. Nature 269 : 338 340.
56. Bianco, J.J. et al. 2002. Direct response of the murine prostate gland and seminal vesicles to estradiol. Endocrinol. 143 : 4922 4933.
57. Bianco, J.J. et al. 2006. Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life. Am. J. Pathol. 168 : 1869 1878.
58. De Marzo, A.M. et al. 1999. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am. J. Pathol. 155 : 1985 1992.
59. Nelson, W.G. et al. 2004. The role of inflammation in the pathogenesis of prostate cancer. J. Urol. 172 : S6 11 discussion S11-2.
60. Palapattu, G.S. et al. 2005. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogen 26 : 1170 1181.
61. Franks, L.M. 1954. Benign nodular hyperplasia of the prostate: A review. Ann. R. Coll. Surgeons 14 : 92 106.
62. Gardner, W.A., Jr. & B.D. Bennett. 1992. The prostate - Overview: Recent insights and speculations. Monogr. Pathol. 129 148.
63. Bostwick, D.G. & M.K. Brawer. 1987. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59 : 788 794.
64. Brawer, M.K. 1992. Prostatic intraepithelial neoplasia: A premalignant lesion. Hum. Pathol. 23 : 242 248.
65. Ho, S.M. & D. Roy. 1994. Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. Cancer Lett. 84 : 155 162.
66. Ricke, W.A. et al. 2006. Steroid hormones stimulate human prostate cancer progression and metastasis. Int. J. Cancer 118 : 2123 2131.
67. Hill, P., L. Garbaczewski & A.R. Walker. 1984. Age, environmental factors and prostatic cancer. Med. Hypotheses 14 : 29 39.
68. Bosland, M.C. 2000. The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. Monogr. 39 66.
69. de Jong, F.H. et al. 1991. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res. 51 : 3445 3450.
70. Akhtar, M. et al. 1982. Mechanistic studies on C-19 demethylation in oestrogen biosynthesis. Biochem. J. 201 : 569 580.
71. Fishman, J. & J. Goto. 1981. Mechanism of estrogen biosynthesis. Participation of multiple enzyme sites in placental aromatase hydroxylations. J. Biol. Chem. 256 : 4466 4471.
72. Simpson, E.R. et al. 1994. Aromatase gene expression in adipose tissue: Relationship to breast cancer. Int. J. Fertil. Menopausal. Stud. 39 : 75 83.
73. Risbridger, G. et al. 2001. Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev. Biol. 229 : 432 442.
74. Ricke, W.A. et al. 2007. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. Faseb J. 22 (5 1512 1520.
75. Raghow, S. et al. 2002. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 62 : 1370 1376.
76. Price, D. et al. 2006. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J. Urol. 176 : 965 970 discussion 970-971.
77. Carani, C. et al. 1997. Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med. 337 : 91 95.
78. Deladoey, J. et al. 1999. Aromatase deficiency caused by a novel P450arom gene mutation: Impact of absent estrogen production on serum gonadotropin concentration in a boy. J. Clin. Endocrinol. Metab. 84 : 4050 4054.
79. Herrmann, B.L. et al. 2002. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J. Clin. Endocrinol. Metab. 87 : 5476 5484.
80. Maffei, L. et al. 2004. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: Effects of testosterone, alendronate, and estradiol treatment. J. Clin. Endocrinol. Metab. 89 : 61 70.
81. Morishima, A. et al. 1995. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80 : 3689 3698.
82. Grumbach, M.M. & R.J. Auchus. 1999. Estrogen: Consequences and implications of human mutations in synthesis and action. J. Clin. Endocrinol. Metab. 84 : 4677 4694.
83. Rochira, V. et al. 2002. Congenital estrogen deficiency in men: A new syndrome with different phenotypes; clinical and therapeutic implications in men. Mol. Cell Endocrinol. 193 : 19 28.
84. Adlercreutz, H. et al. 2000. Phytoestrogens and prostate disease. J. Nutr. 130 : 658S 659S.
85. Griffiths, K. et al. 1998. Phytoestrogens and diseases of the prostate gland. Bailliere's Clin. Endocrinol. Metab. 12 : 625 647.
86. Adlercreutz, H. 1998. Epidemiology of phytoestrogens. Bailliere's Clin. Endocrinol. Metab. 12 : 605 623.
87. Adlercreutz, C.H. et al. 1995. Soybean phytoestrogen intake and cancer risk. J. Nutr. 125 : 757S 770S.
88. Kuiper, G.G. et al. 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93 : 5925 5930.
89. Weihua, Z. et al. 2001. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc. Natl. Acad. Sci. USA 98 : 6330 6335.
90. Imamov, O. et al. 2004. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci. USA 101 : 9375 9380.
91. McPherson, S.J. et al. 2007. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinol. 148 : 566 574.
92. Imamov, O., N.A. Lopatkin & J.A. Gustafsson. 2004. Estrogen receptor beta in prostate cancer. N. Engl. J. Med. 351 : 2773 2774.
93. Chadwick, C.C. et al. 2005. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc. Natl. Acad. Sci. USA 102 : 2543 2548.
94. Harris, H.A. et al. 2003. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinol. 144 : 4241 4249.
95. Prins, G.S. & K.S. Korach. 2008. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 73 : 233 244.
96. Savolainen, S. et al. 2007. Delay of postnatal maturation sensitizes the mouse prostate to testosterone-induced pronounced hyperplasia: Protective role of estrogen receptor-beta. Am. J. Pathol. 171 : 1013 1022.
97. Royuela, M. et al. 2001. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J. Endocrinol. 168 : 447 454.
98. Pasquali, D. et al. 2001. Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J. Clin. Endocrinol. Metab. 86 : 2051 2055.
99. Leav, I. et al. 2001. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159 : 79 92.
100. Horvath, L.G. et al. 2001. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 61 : 5331 5335.
101. Fixemer, T., K. Remberger & H. Bonkhoff. 2003. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54 : 79 87.
102. Bardin, A. et al. 2004. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer 11 : 537 551.
103. Zhu, X. et al. 2004. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol. 164 : 2003 2012.
104. Nojima, D. et al. 2001. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer 92 : 2076 2083.
105. Jarred, R.A. et al. 2002. Induction of apoptosis in low- to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol. Biomarkers Prev. 11 : 1689 1696.
106. Mentor-Marcel, R. et al. 2001. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 61 : 6777 6782.